Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Paul Manganelli

Interventional Pain Medicine Naperville, IL Medical Doctor

NPI 1841247236 CMS profile 356380

120 Spalding Dr, Ste 400, Naperville, IL 60540

Open in the dashboard

General payments

$13,976

212 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Paul Manganelli of Naperville, IL is reported in the CMS Open Payments database as having received $13,976 across 212 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $1,858 31
2024 General $1,554 37
2023 General $2,755 32
2022 General $756 17
2021 General $880 14
2020 General $770 23
2019 General $5,404 58

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Paul Manganelli
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Paul Manganelli were reported at $1,858. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Paul Manganelli Interventional Pain Medicine median Middle half National median
2019 $5,404 $684 $216–$2,079 $163
2020 $770 $382 $122–$1,109 $114
2021 $880 $552 $167–$1,554 $132
2022 $756 $605 $187–$1,924 $149
2023 $2,755 $671 $195–$1,915 $160
2024 $1,554 $684 $206–$1,837 $164
2025 $1,858 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Vertiflex, Inc. $1,913 9 payments
  2. Abbott Laboratories $1,675 23 payments
  3. Boston Scientific Corporation $1,669 30 payments
  4. Nevro Corp. $1,334 41 payments
  5. Saluda Medical Americas, Inc. $1,271 6 payments
  6. Medtronic USA, Inc. $1,185 8 payments
  7. Globus Medical, Inc. $1,164 14 payments
  8. Relievant Medsystems, Inc. $911 7 payments
  9. SPR Therapeutics, Inc $529 9 payments
  10. Nalu Medical, Inc. $372 5 payments
  11. Other $1,954 60 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $8,611 197 payments
  2. Travel and Lodging $4,981 12 payments
  3. Education $384 3 payments
Products named General payments · program years 2019–2025
  1. Superion ISS $1,913 9 payments
  2. OSTEOCOOL RF ABLATION $1,148 5 payments
  3. Evoke SCS $1,098 4 payments
  4. Senza Spinal Cord Stimulation System $1,054 27 payments
  5. Intracept Pain $911 7 payments
  6. Intracept Pain $911 7 payments
  7. Intracept Pain $911 7 payments
  8. Intracept Pain $911 7 payments
  9. Vyrsa V1 $860 8 payments
  10. SPECTRA WAVEWRITER $641 5 payments
  11. Other $6,275 153 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

2,350

Median for Anesthesiology: 322

Drug cost

$104,521

Median for Anesthesiology: $8,738

Branded share of claims

54.5%

Median for Anesthesiology: 25.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Buprenorphine-Naloxone Buprenorphine Hcl/Naloxone Hcl Brand 266 $33,294
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 611 $13,663
Buprenorphine Generic 25 $11,048
Movantik Naloxegol Oxalate Brand 13 $7,678
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 256 $6,309
Suboxone Buprenorphine Hcl/Naloxone Hcl Brand 11 $5,166
Xtampza Er Oxycodone Myristate Brand 14 $4,918
Zubsolv Buprenorphine Hcl/Naloxone Hcl Brand 26 $3,875
Tramadol Hcl Er Tramadol Hcl Brand 12 $3,604
Gabapentin Generic 243 $2,330

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,517 Part D prescribers listed as Anesthesiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 59 billing codes

Paid by Medicare

$209,350

Of which drugs: $2,817

Medicare patients

529

Average age 75

Services billed

8,566

329 women, 200 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 35%
Depression 31%
Diabetes 27%
Chronic kidney disease 26%
Osteoporosis 26%
Heart failure 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 94 1,365 $1,053
Injection, methylprednisolone acetate, 40 mg J1030 Office 12 28 $126
Injection, methylprednisolone acetate, 1 mg J1010 Office 24 1,162 $116

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

4 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Qutenza
  • Averitas Pharma Inc. $152
$152 — —
Zubsolv
  • Orexo US, Inc. $23
$23 26 —
EVENITY
  • Amgen Inc. $8
$8 — —
Prolia
  • Amgen Inc. $8
$8 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record